Medpace MEDP
- Market cap
- $18.1B
- PE
- 38.0×
- 9y median 34.5×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 6.5×
- EV/EBIT
- 30.4×
- Revenue, 12 months
- $2.8B
- +25% on a year ago
- Net margin
- 17.7%
- Free cash flow yield
- 3.9%
Medpace trades at 38.0× trailing earnings, pricier than 66% of the last ten years. Revenue was $2.8B over the last twelve months, up 25% on a year earlier with a 18% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $492.5M+28% | $498.4M+27% | $511M+18% | $528.1M+15% | $533.3M+8% | $536.6M+8% | $558.6M+9% | $603.3M+14% | $659.9M+24% | $708.5M+32% | $706.6M+27% | $707.3M+17% | |
| Cost of revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Gross profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| SG&A | $41.4M+17% | $42.5M+27% | $44.1M+16% | $41.5M+5% | $49.2M+19% | $45.4M+7% | $57.9M+31% | $46.7M+13% | $48.1M−2% | $44.9M−1% | $47.9M−17% | $48.1M+3% |
| $84.9M+9% | $87.3M+14% | $104.1M+21% | $105.2M+34% | $112.3M+32% | $125.4M+44% | $113.5M+9% | $126.3M+20% | $141.8M+26% | $153.3M+22% | $141.5M+25% | $146.8M+16% | |
| Interest expense | $105K−93% | −$1.8M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pre-tax income | $83.2M+2% | $90.7M+23% | $112.8M+31% | $110.5M+46% | $118.8M+43% | $133.9M+48% | $118.2M+5% | $124.5M+13% | $142.8M+20% | $156.8M+17% | $147.6M+25% | $151.7M+22% |
| $12.7M−20% | $12.4M+149% | $10.2M−22% | $22.1M+51% | $22.4M+77% | $16.9M+36% | $3.6M−65% | $34.3M+55% | $31.7M+42% | $21.7M+29% | $23.7M+564% | $30.3M−12% | |
| Net income | $70.5M+7% | $78.3M+14% | $102.6M+41% | $88.4M+45% | $96.4M+37% | $117M+50% | $114.6M+12% | $90.3M+2% | $111.1M+15% | $135.1M+16% | $123.9M+8% | $121.4M+35% |
| $2.22+8% | $2.46+16% | $3.20+41% | $2.75+43% | $3.01+36% | $3.67+49% | $3.67+15% | $3.10+13% | $3.86+28% | $4.66+27% | $4.28+17% | $4.25+37% | |
| 31.8M−2% | 31.8M−2% | 32M−1% | 32.1M+2% | 32.1M+1% | 31.9M+0% | 31.2M−3% | 29.1M−9% | 28.8M−10% | 29M−9% | 29M−7% | 28.6M−2% |
Gross profit: 16 periods, Q3 FY15 to Q2 FY19: not printed by the filing, worked out from its own lines.
EPS, diluted: 7 periods, Q4 FY15 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q4 FY15 and Q4 FY16: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. 9 periods, Q4 FY17 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Diagnostics & Research nearest Medpace's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| MEDPMedpace | $18.1B | 38.0× | 34.5× | n/m | 6.5× | +25% | 17.7% |
| RVTYRevvity | $16.9B | 72.2× | 35.1× | n/m | 5.8× | +4% | 8.2% |
| DGXQuest Diagnostics | $27.5B | 24.9× | 19.3× | n/m | 2.3× | +9% | 9.5% |
| LHLabcorp | $28.9B | 29.4× | 19.5× | 18.8× | 2.0× | +6% | 7.0% |
| BIOBio-Rad Laboratories | $9.8B | 44.4× | 30.9× | n/m | 3.8× | +1% | 8.6% |
| MTDMettler-Toledo International | $34.2B | 38.4× | 36.6× | 34.6× | 8.3× | +7% | 21.9% |
| ILMNIllumina | $35.7B | 44.0× | 51.3× | 41.5× | 8.0× | +5% | 18.4% |
| CAICaris Life Sciences | $9.1B | 86.8× | 78.4× | n/m | 9.2× | +85% | 10.6% |
| IQVIQVIA | $42.5B | 32.0× | 34.8× | 19.0× | 2.5× | +8% | 8.1% |
| WATWaters | $46.4B | 118× | 29.2× | 30.4× | 10.0× | +52% | 3.6% |
| AAgilent Technologies | $49.6B | 34.5× | 33.2× | 26.8× | 6.7× | +9% | 19.5% |
| Peer median | $31.5B | 41.2× | 34.0× | 28.6× | 6.3× | +8% | 9.1% |
Investors who own it
Investors we follow who held Medpace at the end of Jun 30, 2026, from their 13F filings.
- François RochonGiverny Capital4.5% of portfoliotrimmed
- Baillie GiffordBaillie Gifford0.2% of portfoliotrimmed
- Terry SmithFundsmith0.2% of portfoliotrimmed
More on Medpace
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #3of 17Diagnostics and research stocks with the fastest earnings growth
- #8of 42Diagnostics and research stocks with the fastest revenue growth
- #8of 39Diagnostics and research stocks with the highest profit margins
- #10of 28Diagnostics and research stocks with the highest free cash flow yield
- #10of 20Diagnostics and research stocks with the lowest PE ratio
Its groups
About
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .